AbbVie Inc. buy catos
Start price
21.12.19
/
50%
€81.20
Target price
04.11.21
€90.00
Performance (%)
13.05%
End price
23.01.21
€91.80
Summary
This prediction ended on 23.01.21 with a price of €91.80. The BUY prediction by catos finished with a performance of 13.05%. A total of €5.27 was paid as dividends for this prediction. catos has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| AbbVie Inc. | 0.763% | 0.763% | 3.726% | 69.273% |
| iShares Core DAX® | 1.051% | -1.833% | 12.822% | 15.392% |
| iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% | 42.396% |
| iShares Nikkei 225® | -1.778% | -8.115% | 16.092% | 0.891% |
| iShares S&P 500 | 0.002% | -2.226% | 28.387% | 41.095% |
Comments by catos for this prediction
In the thread AbbVie Inc. diskutieren
Kursziel geändert auf 90,0